TY - JOUR
T1 - Predictive factors for outcomes of chemonucleolysis with condoliase in lumbar disc herniation
T2 - A multi-institutional study
AU - Maki, Satoshi
AU - Takahashi, Takuya
AU - Fujii, Shunichi
AU - Sakaeda, Kentaro
AU - Takahashi, Yohei
AU - Watanabe, Kota
AU - Banno, Tomohiro
AU - Sakaki, Kyohei
AU - Arai, Yoshiyasu
AU - Takano, Yuichi
AU - Eguchi, Yawara
AU - Taniguchi, Yuki
AU - Aoki, Yasuchika
AU - Yamada, Hiroshi
AU - Kaito, Takashi
AU - Hiraizumi, Yutaka
AU - Yamagata, Masatsune
AU - Nakamura, Masaya
AU - Haro, Hirotaka
AU - Ohtori, Seiji
AU - Hirai, Takashi
N1 - Publisher Copyright:
© 2025 The Japanese Orthopaedic Association
PY - 2026/5
Y1 - 2026/5
N2 - Background: Chemonucleolysis with condoliase is a minimally invasive treatment for lumbar disc herniation (LDH). However, optimal patient selection criteria remain unclear. This study aimed to identify predictive factors for successful condoliase therapy in LDH, focusing on low back pain (LBP) and leg pain improvement. Methods: This multi-institutional observational study included 238 patients who underwent intradiscal condoliase injection for LDH. Demographic and clinical data were collected, including pain intensity using the Numeric Rating Scale (NRS) for leg and back pain at baseline, 3–6 months, and 12 months. MRI assessments evaluated disc height, Pfirrmann grade, and herniation occupancy ratio. The primary outcome was defined as achieving the minimum clinically important difference (MCID) on the 0–10 NRS, defined as an improvement of ≥2 points at 3–6 months or 12 months, without additional surgery during follow-up. Multivariable logistic regression was used to identify predictors of MCID achievement. Results: Condoliase was effective, with over 70 % of patients achieving MCID for leg pain and over 50 % for LBP. For LBP at 3–6 months, higher baseline back pain intensity (OR 3.09, 95 % CI 2.00–4.78), lower MRI slip (OR 0.59, 95 % CI 0.38–0.92), higher MRI occupancy rate (OR 1.74, 95 % CI 1.19–2.54), and L5/S1 injection level (OR 2.20, 95 % CI 1.06–4.54) predicted MCID achievement. At 12 months, higher baseline back pain intensity (OR 2.26, 95 % CI 1.49–3.44), higher MRI occupancy rate (OR 1.85, 95 % CI 1.24–2.79), shorter disease duration (OR 0.57, 95 % CI 0.38–0.86), and absence of X-ray posterior slip (presence: OR 0.18, 95 % CI 0.04–0.91) were associated with MCID achievement. For leg pain at 3–6 months, lower MRI slip (OR 0.60, 95 % CI 0.41–0.89) and higher baseline leg pain intensity (OR 1.72, 95 % CI 1.23–2.41) were associated with MCID achievement. For leg pain at 12 months, shorter disease duration (OR 0.61, 95 % CI 0.42–0.88), lower X-ray slip (OR 0.54, 95 % CI 0.30–0.97), higher baseline leg pain intensity (OR 1.94, 95 % CI 1.30–2.88), and lower Pfirrmann grade (OR 0.48, 95 % CI 0.23–0.99) were predictive of MCID achievement. Conclusions: This study identified key factors associated with successful outcomes of condoliase in LDH. Baseline pain intensity, MRI findings (herniation occupancy rate, slip), injection level, and disease duration were significant predictors of treatment outcomes. These findings may aid clinicians in patient selection and improve treatment success.
AB - Background: Chemonucleolysis with condoliase is a minimally invasive treatment for lumbar disc herniation (LDH). However, optimal patient selection criteria remain unclear. This study aimed to identify predictive factors for successful condoliase therapy in LDH, focusing on low back pain (LBP) and leg pain improvement. Methods: This multi-institutional observational study included 238 patients who underwent intradiscal condoliase injection for LDH. Demographic and clinical data were collected, including pain intensity using the Numeric Rating Scale (NRS) for leg and back pain at baseline, 3–6 months, and 12 months. MRI assessments evaluated disc height, Pfirrmann grade, and herniation occupancy ratio. The primary outcome was defined as achieving the minimum clinically important difference (MCID) on the 0–10 NRS, defined as an improvement of ≥2 points at 3–6 months or 12 months, without additional surgery during follow-up. Multivariable logistic regression was used to identify predictors of MCID achievement. Results: Condoliase was effective, with over 70 % of patients achieving MCID for leg pain and over 50 % for LBP. For LBP at 3–6 months, higher baseline back pain intensity (OR 3.09, 95 % CI 2.00–4.78), lower MRI slip (OR 0.59, 95 % CI 0.38–0.92), higher MRI occupancy rate (OR 1.74, 95 % CI 1.19–2.54), and L5/S1 injection level (OR 2.20, 95 % CI 1.06–4.54) predicted MCID achievement. At 12 months, higher baseline back pain intensity (OR 2.26, 95 % CI 1.49–3.44), higher MRI occupancy rate (OR 1.85, 95 % CI 1.24–2.79), shorter disease duration (OR 0.57, 95 % CI 0.38–0.86), and absence of X-ray posterior slip (presence: OR 0.18, 95 % CI 0.04–0.91) were associated with MCID achievement. For leg pain at 3–6 months, lower MRI slip (OR 0.60, 95 % CI 0.41–0.89) and higher baseline leg pain intensity (OR 1.72, 95 % CI 1.23–2.41) were associated with MCID achievement. For leg pain at 12 months, shorter disease duration (OR 0.61, 95 % CI 0.42–0.88), lower X-ray slip (OR 0.54, 95 % CI 0.30–0.97), higher baseline leg pain intensity (OR 1.94, 95 % CI 1.30–2.88), and lower Pfirrmann grade (OR 0.48, 95 % CI 0.23–0.99) were predictive of MCID achievement. Conclusions: This study identified key factors associated with successful outcomes of condoliase in LDH. Baseline pain intensity, MRI findings (herniation occupancy rate, slip), injection level, and disease duration were significant predictors of treatment outcomes. These findings may aid clinicians in patient selection and improve treatment success.
KW - Chemonucleolysis
KW - Condoliase
KW - Lumbar disc herniation
KW - Predictive factors
UR - https://www.scopus.com/pages/publications/105025473635
UR - https://www.scopus.com/pages/publications/105025473635#tab=citedBy
U2 - 10.1016/j.jos.2025.11.009
DO - 10.1016/j.jos.2025.11.009
M3 - Article
C2 - 41419388
AN - SCOPUS:105025473635
SN - 0949-2658
VL - 31
SP - 541
EP - 548
JO - Journal of Orthopaedic Science
JF - Journal of Orthopaedic Science
IS - 3
ER -